TransCode Therapeutics, Inc.

TransCode Therapeutics, Inc.verified

RNAZ

Price:

$8.6357

Market Cap:

$7.92M

TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. Its cancer agnostic programs comprise TTX-RIGA, an RNA–based agonist of the RIG-I-driven immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9–based therapy platform for the repair or eliminati...[Read more]

Industry

Biotechnology

IPO Date

2021-07-08

Stock Exchange

NASDAQ

Ticker

RNAZ

The PE Ratio as of December 2025 (TTM) for TransCode Therapeutics, Inc. (RNAZ) is -0.04

According to TransCode Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.04. This represents a change of -88.77% compared to the average of -0.36 of the last 4 quarters.

TransCode Therapeutics, Inc. (RNAZ) Historical PE Ratio (quarterly & annually)

How has RNAZ PE Ratio performed in the past?

The mean historical PE Ratio of TransCode Therapeutics, Inc. over the last ten years is -4892.19. The current -0.04 PE Ratio has changed -99.92% with respect to the historical average. Over the past ten years (40 quarters), RNAZ's PE Ratio was at its highest in in the June 2021 quarter at 1.74K. The PE Ratio was at its lowest in in the March 2020 quarter at -104736.92.

Quarterly (TTM)
Annual

Average

-4892.19

Median

-1160.30

Minimum

-22950.69

Maximum

-1.25

TransCode Therapeutics, Inc. (RNAZ) PE Ratio by Quarter and Year

Discovering the peaks and valleys of TransCode Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 1.88%

Maximum Annual PE Ratio = -1.25

Minimum Annual Increase = -99.22%

Minimum Annual PE Ratio = -22950.69

Quarterly (TTM)
Annual
YearPE RatioChange
2024-1.4012.59%
2023-1.25-99.22%
2022-160.80-91.94%
2021-1994.99-74.99%
2020-7975.88-65.25%
2019-22950.691.88%

TransCode Therapeutics, Inc. (RNAZ) Average PE Ratio

How has RNAZ PE Ratio performed in the past?

The current PE Ratio of TransCode Therapeutics, Inc. (RNAZ) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

-54.48

5-year avg

-2026.86

10-year avg

-4892.19

TransCode Therapeutics, Inc. (RNAZ) PE Ratio vs. Peers

How is RNAZ’s PE Ratio compared to its peers?

TransCode Therapeutics, Inc.’s PE Ratio is greater than IN8bio, Inc. (-0.40), greater than Lyra Therapeutics, Inc. (-0.16), greater than Aptevo Therapeutics Inc. (-0.04), greater than Galecto, Inc. (-1.92), greater than Phio Pharmaceuticals Corp. (-9.28), greater than HCW Biologics Inc. (-0.21), greater than Kiora Pharmaceuticals, Inc. (-0.72), greater than Aprea Therapeutics, Inc. (-0.47), greater than Bolt Biotherapeutics, Inc. (-0.24), less than Acurx Pharmaceuticals, Inc. (-0.00),

Build a custom stock screener for TransCode Therapeutics, Inc. (RNAZ) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like TransCode Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

TransCode Therapeutics, Inc. (RNAZ) and other stocks custom spreadsheet templates

The easiest way to analyze a company like TransCode Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is TransCode Therapeutics, Inc.'s PE Ratio?

How is the PE Ratio calculated for TransCode Therapeutics, Inc. (RNAZ)?

What is the highest PE Ratio for TransCode Therapeutics, Inc. (RNAZ)?

What is the 3-year average PE Ratio for TransCode Therapeutics, Inc. (RNAZ)?

What is the 5-year average PE Ratio for TransCode Therapeutics, Inc. (RNAZ)?

How does the current PE Ratio for TransCode Therapeutics, Inc. (RNAZ) compare to its historical average?